Vaccine evaluation-Varicella vaccine
Immunogenicity and safety of combined immunization of healthy children with varicella vaccine and measles, mumps and rubella vaccine
Xiaodong Sun, Xianghu Ma, Zhi Li, Yunyi Li, Yanli Ma, Xiuying Zhang, Qingxiao Huang, Dandan Chen, Hong Pang, Xiaoqin Liu, Jie Fei, Xiaofang Lin, Bin Xu, Haiping Chen
Published 2016-03-31
Cite as Chin J Microbiol Immunol, 2016, 36(3): 182-188. DOI: 10.3760/cma.j.issn.0254-5101.2016.03.005
Abstract
ObjectiveTo evaluate the immunogenicity and safety of combined vaccination of healthy children with varicella vaccine and measles, mumps and rubella (MMR) vaccine and to provide a guidance for reasonable arrangement of immunization schedule.
MethodsHealthy and eligible children aged 17-24 months were recruited and divided into three groups. Subjects in the three groups were respectively immunized with varicella or MMR vaccine alone or in combination. Blood samples were collected from the subjects before and 35-42 days after vaccination for the detection of seroprevalence. Subjects were also asked to fill in safety observation forms 30 minutes, 24, 48, 72 hours and 7, 14, 30 days after vaccination. Each group contained no less than 100 subjects. Statistical analysis was conducted by using χ2 test, Fisher's exact test and non-parametric test.
ResultsA total of 445 subjects completed the serologic detection and 450 completed the safety observation. Seropositive rates and geometric mean titers (or concentrations) (GMT or GMC) of antibodies against varicella, measles, mumps and rubella were all significantly increased after immunizing the subjects of different groups with corresponding vaccination strategies. The seropositive rates, seroconversion rates and antibody levels of the combined immunization group were higher than those of the other two groups. Subjects in the MMR group who were negative for anti-mumps antibody before vaccination showed significantly higher GMC of anti-mumps antibody than those in combined immunization group. Subjects in MMR group with positive results of anti-rubella antibody showed significantly higher GMC of anti-rubella antibody than those in combined immunization group. Adverse reactions were reported in 23 subjects with a rate of 5.11%. All of the 23 cases were manifested as moderate or severe fever and one was accompanied with rash. No significant differences in the incidence rates of adverse reactions were observed between three groups.
ConclusionImmunizing children aged 18-23 months with varicella vaccine or MMR vaccine alone or in combination could significantly increase the seropositive rates and antibody levels. Adverse reactions caused by the combined immunization were mainly fever and rash. No significant difference in the incidence rates was found between the combined vaccination group and the other two groups. The titers of antibody against varicella in subjects immunized with both varicella and MMR vaccines were significantly higher than those immunized with varicella vaccine alone. No significant difference in the levels of antibodies against measles, rubella and mumps was found between the MMR vaccination group and the combined vaccination group. However, considering the limitation of this study, these results still need further study for verification.
Key words:
Varicella vaccine; Measles, mumps and rubella (MMR) vaccine; Combined immunization; Immunogenicity; Safety
Contributor Information
Xiaodong Sun
Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
Xianghu Ma
Shanghai Institute of Biological Products Company Limited, Shanghai 200052, China
Zhi Li
Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
Yunyi Li
Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
Yanli Ma
China National Biotec Group Company Limited, Beijing 100029, China
Xiuying Zhang
Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China
Qingxiao Huang
China National Biotec Group Company Limited, Beijing 100029, China
Dandan Chen
Shanghai Institute of Biological Products Company Limited, Shanghai 200052, China
Hong Pang
Shanghai Changning District Center for Disease Control and Prevention, Shanghai 200051, China
Xiaoqin Liu
China National Biotec Group Company Limited, Beijing 100029, China
Jie Fei
Shanghai Jiading District Center for Disease Control and Prevention, Shanghai 201800, China
Xiaofang Lin
Shanghai Chongming County Center for Disease Control and Prevention, Shanghai 202150, China
Bin Xu
China National Biotec Group Company Limited, Beijing 100029, China
Haiping Chen
China National Biotec Group Company Limited, Beijing 100029, China